NYSE:AB
AllianceBernstein Holding LP Stock News
$33.16
-0.120 (-0.361%)
At Close: May 03, 2024
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
02:02pm, Wednesday, 19'th Oct 2022 Benzinga
Upgrades
According to Raymond James, the prior rating for Fortis Inc (NYSE:FTS) was changed from Market Perform to Outperform. In the second quarter, Fortis showed an EPS of $0.45, compared to $0.45 f
AB to Report Third Quarter 2022 Results on October 28, 2022
12:08pm, Friday, 14'th Oct 2022
NASHVILLE, Tenn. , Oct. 14, 2022 /PRNewswire/ -- AllianceBernstein L.P.
Zacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE
09:26am, Wednesday, 12'th Oct 2022 Zacks Investment Research
Terns Pharmaceuticals, AllianceBernstein Holding and ALLETE have been highlighted in this Screen of The Week article.
11 October Inflation Busting Dividend Dogs Ready To Buy
10:45pm, Tuesday, 11'th Oct 2022
March-April, 2022, UBS, Kiplinger, and Barron's analysts and reporters combined to list five-sets of stocks sorted-as: “Inflation Busters for 2022.” Those five-articles revealed 48 equities, with
3 Stocks for Higher Returns as New Analysts Initiate Coverage
12:54pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), AllianceBernstein (AB) and ALLETE (ALE).
3 Stocks for Higher Returns as New Analysts Initiate Coverage
10:32am, Tuesday, 11'th Oct 2022
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), AllianceBernstein (AB) and ALLETE (ALE).
AB Science a reçu les premières autorisations règlementaires pour initier une étude clinique confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
04:04pm, Monday, 10'th Oct 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease
04:04pm, Monday, 10'th Oct 2022 GlobeNewswire Inc.
PRESS RELEASE
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2022 et présente un point sur ses activités
04:39pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
04:39pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
PRESS RELEASE
These Are 10 Asset Management Companies With A High Payout Ratio
08:50pm, Monday, 26'th Sep 2022
Payout ratio isn't among the top of the list for most investors when they analyze a stock for investment, but it is an important indicator of what stage of business a company is in.
Lazard's (LAZ) August AUM Slips 3.6% on Market Depreciation
03:22pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Market depreciation, unfavorable FX movements and net outflows hurt Lazard's (LAZ) August AUM balance.
AB Science - Recommandation favorable du comité indépendant de revue des données de poursuivre l’étude de Phase 2 évaluant l’activité antivirale du masitinib dans le traitement du Covid-19
04:21pm, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
COMMUNIQUE DE PRESSE
AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19
04:21pm, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
PRESS RELEASE
Invesco's (IVZ) August AUM Down on Unfavorable Market Returns
01:54pm, Tuesday, 13'th Sep 2022 Zacks Investment Research
Market depreciation, unfavorable FX movements and non-management fee-earning net outflows hurt Invesco's (IVZ) August AUM balance as it falls 2.3% from the prior month.
